|
Re: ZZXY
|
2
|
Zenith Epigenetics
|
May 13, 2018 08:41PM
|
|
Re: Happy Anniversary....
|
4
|
Resverlogix Corp.
|
May 13, 2018 10:31PM
|
|
Re: The Feb 26th DSMB PR.....re-examined.
|
2
|
Resverlogix Corp.
|
May 14, 2018 07:10AM
|
|
Re: The Feb 26th DSMB PR.....re-examined.
|
1
|
Resverlogix Corp.
|
May 14, 2018 07:25AM
|
|
Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
|
1
|
BIOASIS TECHNOLOGIES INC
|
May 14, 2018 10:23AM
|
|
Re: Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
|
2
|
BIOASIS TECHNOLOGIES INC
|
May 14, 2018 10:45AM
|
|
Re: The Feb 26th DSMB PR.....re-examined.
|
7
|
Resverlogix Corp.
|
May 14, 2018 12:25PM
|
|
Re: ZZXY
|
3
|
Zenith Epigenetics
|
May 14, 2018 12:28PM
|
|
Re: Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
|
1
|
BIOASIS TECHNOLOGIES INC
|
May 14, 2018 12:35PM
|
|
Re: FA
|
12
|
Resverlogix Corp.
|
May 15, 2018 02:47PM
|
|
Re: Is CellCentric a competitor?
|
4
|
Zenith Epigenetics
|
May 15, 2018 10:47PM
|
|
Re: Now is the time over late spring and summer
|
2
|
Resverlogix Corp.
|
May 16, 2018 10:17AM
|
|
Re: BIO International 2018
|
3
|
Zenith Epigenetics
|
May 16, 2018 11:18AM
|
|
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
|
2
|
Zenith Epigenetics
|
May 16, 2018 11:35AM
|
|
ASCO abstracts and "-bresib" nomenclature
|
5
|
Zenith Epigenetics
|
May 16, 2018 05:58PM
|
|
Re: BETonMACE details
|
6
|
Resverlogix Corp.
|
May 16, 2018 08:11PM
|
|
Re: BETonMACE details
|
6
|
Resverlogix Corp.
|
May 16, 2018 08:32PM
|
|
Re: BETonMACE details
|
7
|
Resverlogix Corp.
|
May 16, 2018 09:07PM
|
|
Re: BETonMACE details
|
5
|
Resverlogix Corp.
|
May 16, 2018 10:18PM
|
|
Re: BETonMACE details
|
4
|
Resverlogix Corp.
|
May 16, 2018 11:08PM
|
